Analysts expect BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to post earnings per share (EPS) of ($0.28) for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for BioCryst Pharmaceuticals’ earnings, with estimates ranging from ($0.33) to ($0.25). BioCryst Pharmaceuticals reported earnings per share of ($0.26) during the same quarter last year, which would indicate a negative year-over-year growth rate of 7.7%. The company is expected to issue its next quarterly earnings report on Tuesday, May 14th.
According to Zacks, analysts expect that BioCryst Pharmaceuticals will report full year earnings of ($1.19) per share for the current financial year, with EPS estimates ranging from ($1.30) to ($1.09). For the next financial year, analysts expect that the business will post earnings of ($1.15) per share, with EPS estimates ranging from ($1.35) to ($0.95). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover BioCryst Pharmaceuticals.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Monday, March 4th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.01. The business had revenue of $2.73 million for the quarter, compared to analysts’ expectations of $2.39 million. BioCryst Pharmaceuticals had a negative return on equity of 175.83% and a negative net margin of 490.25%.
In other BioCryst Pharmaceuticals news, VP Lynne Powell sold 12,000 shares of the firm’s stock in a transaction dated Monday, January 28th. The stock was sold at an average price of $9.75, for a total transaction of $117,000.00. Following the transaction, the vice president now owns 6,000 shares of the company’s stock, valued at $58,500. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Thomas R. Staab II sold 5,000 shares of the firm’s stock in a transaction dated Monday, January 28th. The stock was sold at an average price of $9.85, for a total value of $49,250.00. Following the transaction, the chief financial officer now directly owns 133,426 shares in the company, valued at approximately $1,314,246.10. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 35,546 shares of company stock worth $336,961. Corporate insiders own 4.50% of the company’s stock.
Hedge funds have recently modified their holdings of the business. Paloma Partners Management Co acquired a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter worth about $84,000. Amalgamated Bank acquired a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter worth about $122,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of BioCryst Pharmaceuticals during the third quarter worth about $122,000. Legal & General Group Plc boosted its stake in shares of BioCryst Pharmaceuticals by 14.5% during the fourth quarter. Legal & General Group Plc now owns 19,315 shares of the biotechnology company’s stock worth $156,000 after buying an additional 2,453 shares during the period. Finally, Raymond James Financial Services Advisors Inc. acquired a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter worth about $232,000. 91.90% of the stock is currently owned by institutional investors.
NASDAQ:BCRX opened at $8.53 on Friday. The firm has a market capitalization of $965.15 million, a P/E ratio of -8.70 and a beta of 1.80. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.62 and a current ratio of 1.65. BioCryst Pharmaceuticals has a 12 month low of $4.76 and a 12 month high of $9.95.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.
Featured Story: What is a stock buyback?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.